INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67601, 'Anisindione', 'Clarithromycin', 'Major', 'Coadministration with clarithromycin or erythromycin may infrequently but substantially enhance the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism of interaction is unknown. Data from clinical studies have not supported a significant, predictable pharmacodynamic or pharmacokinetic interaction in general. Although both macrolides are potent inhibitors of CYP450 3A4 and can inhibit metabolism of the R(+) enantiomer of warfarin, the overall effect on racemic warfarin pharmacokinetics appears to be minor.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones) and other similar macrolides (e.g., troleandomycin), although clinical data are lacking.', 'Metabolism', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67688/', '', 'Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Ranitidine, Vonoprazan, Dirithromycin, Lincomycin, Troleandomycin, Clindamycin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67602, 'Clarithromycin', 'Astemizole', 'Major', 'Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may significantly increase the plasma concentrations of astemizole and terfenadine. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of astemizole and terfenadine. High plasma levels of these agents have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.', 'DDInter', 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of astemizole and terfenadine, the use of these agents with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated. Loratadine, cetirizine, or fexofenadine may be safer alternatives during therapy with telithromycin or macrolides. Depending on organism susceptibility, azithromycin and dirithromycin may be appropriate alternatives during therapy with astemizole or terfenadine.', 'Metabolism', 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of astemizole and terfenadine, the use of these agents with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67689/', '', 'Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67603, 'Clarithromycin', 'Bacampicillin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67690/', '', 'Tinidazole, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Vonoprazan, Amoxicillin, Telithromycin, Lincomycin, More', 'Tazobactam, Sulbactam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67604, 'Clarithromycin', 'Bedaquiline', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to its less active N-monodesmethyl metabolite, M2. Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Concomitant use of potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk. Because these agents may also cause QT interval prolongation, caution is recommended when they are used together with bedaquiline. ECG, serum electrolytes (potassium, magnesium, calcium), and liver function tests (ALT, AST, alkaline phosphatase, bilirubin) should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration. All QT-prolonging drugs including bedaquiline should be interrupted in patients who develop clinically significant ventricular arrhythmia or a QTcF interval greater than 500 msec confirmed by repeat ECG.', 'Metabolism, Synergism', 'Concomitant use of potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67691/', '', 'Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More', 'Capreomycin, Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67605, 'Clarithromycin', 'Bepridil', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67692/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67606, 'Clarithromycin', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat. Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors. Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Absorption', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67693/', '', 'Rabeprazole, Dexlansoprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67607, 'Clarithromycin', 'Bifidobacterium longum infantis', 'Moderate', 'INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67694/', '', 'Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67608, 'Clarithromycin', 'Boceprevir', 'Moderate', 'Coadministration of a macrolide or ketolide antibiotic (clarithromycin, erythromycin, telithromycin) with a hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) is expected to increase the plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. No pharmacokinetic data are currently available. Clinically, high plasma levels of macrolide or ketolide antibiotics may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.', 'DDInter', 'Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.', 'Metabolism', 'Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67695/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67609, 'Clarithromycin', 'Carbenicillin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67696/', '', 'Tazobactam, Sulbactam', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67610, 'Frangula purshiana bark', 'Clarithromycin', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67697/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67611, 'Clarithromycin', 'Castor oil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67698/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67612, 'Clarithromycin', 'Cerivastatin', 'Major', 'Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.', 'DDInter', 'The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of the HMG-CoA reductase inhibitor should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with clarithromycin. Fluvastatin, pitavastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67699/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More', 'Amoxicillin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, Esomeprazole, Levofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67613, 'Clarithromycin', 'Chlorpromazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67700/', '', 'Loxapine, Molindone, Thiothixene', 'Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67614, 'Clarithromycin', 'Cisapride', 'Major', 'Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may significantly increase the plasma concentrations of cisapride. The mechanism is inhibition of cisapride metabolism via CYP450 3A4. High plasma levels of cisapride have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.', 'DDInter', 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the use of cisapride with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67701/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67615, 'Clindamycin', 'Clarithromycin', 'Moderate', 'Coadministration with strong CYP450 3A4 inhibitors may increase plasma concentrations and the risk of adverse effects of clindamycin, which is metabolized predominantly by the isoenzyme.', 'DDInter', 'Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors. The possibility of adverse reactions to clindamycin should be considered during coadministration with strong CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring of clindamycin should be considered whenever a strong CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67702/', '', 'Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Clarithromycin, Lincomycin, Troleandomycin, Dirithromycin, Tinidazole, Ascorbic acid, More', 'Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, Dirithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67616, 'Clobazam', 'Clarithromycin', 'Moderate', 'Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.', 'DDInter', 'Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.', 'Metabolism', 'Patients receiving this combination should be monitored for excessive or prolonged sedation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67703/', '', 'Meprobamate', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67617, 'Clofarabine', 'Clarithromycin', 'Moderate', 'The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.', 'DDInter', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67704/', '', 'Fluorouracil, Cladribine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine', 'Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67618, 'Clofazimine', 'Clarithromycin', 'Moderate', 'Clofazimine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval. Consider monitoring electrocardiograms, particularly in patients receiving clofazimine dosages greater than 100 mg/day, and discontinue QT-prolonging medications if clinically significant ventricular arrhythmia is noted or if QTcF interval >=500 ms is observed. If syncope occurs, obtain an ECG to detect QT prolongation.', 'Synergism', 'Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67705/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67619, 'Clomipramine', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67706/', '', 'Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Vonoprazan, Amoxicillin, Dirithromycin, More', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67620, 'Clonazepam', 'Clarithromycin', 'Moderate', 'Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.', 'DDInter', 'Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.', 'Metabolism', 'Patients receiving this combination should be monitored for excessive or prolonged sedation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67707/', '', 'Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67621, 'Clopidogrel', 'Clarithromycin', 'Moderate', 'The concomitant administration of some macrolide antibiotics may reduce the metabolic activation of the prodrug clopidogrel and its antiplatelet effects. The proposed mechanism is inhibition of CYP450 3A4 enzymatic activity, which is responsible for the conversion of clopidogrel to its active metabolite.', 'DDInter', 'Until more information is available, monitoring for altered efficacy of clopidogrel may be advisable if a macrolide is coadministered with clopidogrel. Azithromycin and dirithromycin do not inhibit CYP450 3A4 and are theoretically not expected to interact with clopidogrel.', 'Metabolism', 'Until more information is available, monitoring for altered efficacy of clopidogrel may be advisable if a macrolide is coadministered with clopidogrel.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67708/', '', 'Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 'Tinidazole, Bismuth subcitrate potassium, Levofloxacin, Rifabutin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67622, 'Clorazepic acid', 'Clarithromycin', 'Moderate', 'Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.', 'DDInter', 'Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.', 'Metabolism', 'Patients receiving this combination should be monitored for excessive or prolonged sedation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67709/', '', 'Meprobamate', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67623, 'Cloxacillin', 'Clarithromycin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67710/', '', 'Tazobactam, Sulbactam', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67624, 'Clozapine', 'Clarithromycin', 'Moderate', 'The concomitant administration of some macrolides may result in decreased clearance of clozapine and increased risk of toxicity. The mechanism of this interaction is suspected to be inhibition of the CYP450 hepatic metabolism of clozapine.', 'DDInter', 'While clinical data are limited, clinical and laboratory monitoring may be appropriate whenever a macrolide is added to or withdrawn from therapy. Alternatively, azithromycin and dirithromycin may be considered, as they do not inhibit CYP450 and are not expected to affect clozapine metabolism. Patients should be advised to report symptoms such as somnolence, disorientation, slurred speech, seizures, uncontrolled movements, dizziness, irregular heartbeat, palpitations, fever, or hypersalivation to their physician.', 'Metabolism', 'While clinical data are limited, clinical and laboratory monitoring may be appropriate whenever a macrolide is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67711/', '', 'Loxapine, Molindone, Thiothixene', 'Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Vonoprazan, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67625, 'Cobicistat', 'Clarithromycin', 'Moderate', 'Coadministration of a macrolide or ketolide antibiotic (clarithromycin, erythromycin, telithromycin) with cobicistat is expected to increase the plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. No pharmacokinetic data are currently available. Clinically, high plasma levels of macrolide or ketolide antibiotics may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.', 'DDInter', 'Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with cobicistat. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope. Some authorities recommend avoiding the concomitant use of fixed combination antiretroviral products containing cobicistat with these antibiotics. For clarithromycin, a dosage reduction by 50% has been recommended in patients with CrCl between 30 and 60 mL/min. However, in patients receiving atazanavir or ritonavir concomitantly with clarithromycin, it has been suggested that the dose of clarithromycin be reduced by 75% in patients with a CrCl of less than 30 mL/min. A similar dosage reduction may be appropriate when clarithromycin is used with cobicistat.', 'Metabolism', 'Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with cobicistat.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67712/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67626, 'Cobimetinib', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.', 'DDInter', 'Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of cobimetinib during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67713/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67627, 'Colchicine', 'Clarithromycin', 'Major', 'Coadministration of colchicine with clarithromycin may significantly increase the serum concentrations of colchicine. The proposed mechanism is inhibition of the CYP450 3A4-mediated metabolism and P-glycoprotein (P-gp)-mediated transport of colchicine by clarithromycin. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.', 'DDInter', 'Due to the risk of life-threatening and fatal toxicity, concomitant use of colchicine with clarithromycin should generally be avoided if possible. Otherwise, caution is advised. Coadministration of colchicine with clarithromycin in patients with renal or hepatic impairment is considered contraindicated. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with potent CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the recommended dosage is 0.6 mg for one dose, followed by 0.3 mg one hour later. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg once a day if the original regimen was 0.6 mg twice a day, and 0.3 mg once every other day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 0.6 mg/day (may be given as 0.3 mg twice a day) when used in the presence of potent CYP450 3A4 inhibitors. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paraesthesia, and numbness.', 'Metabolism', 'Due to the risk of life-threatening and fatal toxicity, concomitant use of colchicine with clarithromycin should generally be avoided if possible.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67714/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, More', 'Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67628, 'Conivaptan', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vasopressin receptor antagonists conivaptan and tolvaptan, both of which are almost exclusively metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities recommend avoiding concomitant use of conivaptan or tolvaptan during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67715/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67629, 'Conjugated estrogens (topical)', 'Clarithromycin', 'Moderate', 'RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.', 'DDInter', 'Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67716/', '', 'Bazedoxifene', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67630, 'Copanlisib', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67717/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67631, 'Crizotinib', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. Because crizotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', 'DDInter', 'Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of crizotinib during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67718/', '', 'Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67632, 'Cyclosporine', 'Clarithromycin', 'Major', 'Coadministration with macrolide antibiotics that are potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.', 'DDInter', 'Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative antibiotics that do not interfere with cyclosporine metabolism should be considered whenever possible.', 'Metabolism', 'Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67719/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More', 'Vonoprazan, Bismuth subcitrate potassium, Levofloxacin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67633, 'Dabrafenib', 'Clarithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67720/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Esomeprazole, Amoxicillin, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67634, 'Daclatasvir', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.', 'DDInter', 'A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67721/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67635, 'Dapagliflozin', 'Clarithromycin', 'Moderate', 'Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.', 'DDInter', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Metabolism', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67722/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67636, 'Darifenacin', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by the isoenzyme. Darifenacin is also metabolized by CYP450 2D6, but 3A4 is the major pathway of metabolism in so-called poor metabolizers of 2D6 (approximately 7% of Caucasians and 2% of Asians and those of African descent).', 'DDInter', 'The dosage of darifenacin should not exceed 7.5 mg/day when used with CYP450 3A4 inhibitors such as ketolide and certain macrolide antibiotics.', 'Metabolism', 'The dosage of darifenacin should not exceed 7.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67723/', '', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Nizatidine, Esomeprazole, Amoxicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67637, 'Darolutamide', 'Clarithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 that can also inhibit P-glycoprotein (P-gp) may significantly increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter.', 'DDInter', 'Caution is advised when darolutamide is used with dual P-gp and potent CYP450 3A4 inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when darolutamide is used with dual P-gp and potent CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67724/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67638, 'Darunavir', 'Clarithromycin', 'Moderate', 'Coadministration with darunavir/ritonavir may increase the plasma concentrations of clarithromycin. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of clarithromycin.Clarithromycin had no significant effect on the pharmacokinetics of darunavir.', 'DDInter', 'No dosage adjustment of clarithromycin or darunavir is required during coadministration in patients with normal renal function. However, clarithromycin dosage should be reduced by 50% in patients with moderate renal impairment (CrCl 30 to 60 mL/min) and 75% in patients with more severe renal impairment (CrCl below 30 mL/min).', 'Metabolism', 'No dosage adjustment of clarithromycin or darunavir is required during coadministration in patients with normal renal function.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67725/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67639, 'Dasatinib', 'Clarithromycin', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of dasatinib during and for 2 weeks after treatment with itraconazole. Close monitoring for toxicity (e.g., myelosuppression, bleeding complications, fluid retention, excessive slowing of heart rate or other conduction disturbances) and a reduction of dasatinib dosage to a range of 20 to 40 mg daily should be considered if there are no alternatives and concomitant use with these agents is necessary.', 'Metabolism', 'Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67726/', '', 'Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67640, 'Daunorubicin', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', 'DDInter', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67727/', '', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin, Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, More', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67641, 'Daunorubicin (liposomal)', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', 'DDInter', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67728/', '', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin, Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, More', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67642, 'Deferasirox', 'Clarithromycin', 'Moderate', 'Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.', 'DDInter', 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67729/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67643, 'Deflazacort', 'Clarithromycin', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.', 'DDInter', 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of deflazacort and CYP450 3A inhibitors unless the benefit outweighs the risk, in which case patients should be monitored for systemic corticosteroid side effects.', 'Metabolism', 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67730/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67644, 'Degarelix', 'Clarithromycin', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67731/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67645, 'Delavirdine', 'Clarithromycin', 'Moderate', 'Concomitant administration of delavirdine and clarithromycin has been shown to increase the area under the plasma concentration-time curve (AUC) of clarithromycin by 100%. The mechanism may be related to inhibition of CYP450 3A4 hepatic metabolism.', 'DDInter', 'Close clinical monitoring for toxicity is recommended if this combination is used. The manufacturer recommends dose adjustments for clarithromycin in patients with renal insufficiency: Reduce the dose by 50% for patients with a creatinine clearance of 30 to 60 mL/min, and reduce by 75% for patients with creatinine clearance less than 30 mL/min.', 'Metabolism', 'Close clinical monitoring for toxicity is recommended if this combination is used.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67732/', '', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 'Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67646, 'Desipramine', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67733/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67647, 'Deutetrabenazine', 'Clarithromycin', 'Moderate', 'Deutetrabenazine has been associated with modest QT interval prolongation. In addition, central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking deutetrabenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Deutetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. If concomitant use is required, assessment of baseline QT interval and periodic monitoring during therapy may be considered. In addition, dosage reduction may be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor, or in patients who are poor metabolizers of CYP450 2D6.', 'Metabolism, Synergism', 'Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67734/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67648, 'Dexamethasone (nasal)', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67735/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, Fluorometholone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67649, 'Dexamethasone (ophthalmic)', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67736/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, Fluorometholone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67650, 'Dexlansoprazole', 'Clarithromycin', 'Moderate', 'Coadministration with clarithromycin may increase the plasma concentrations of lansoprazole. The proposed mechanism is clarithromycin inhibition of intestinal (first-pass) and hepatic metabolism of lansoprazole via CYP450 3A4. Although lansoprazole is primarily metabolized by CYP450 2C19 in the liver, 3A4-mediated metabolism is the predominant pathway in individuals who are 2C19-deficient (approximately 3% to 5% of the Caucasian and 17% to 20% of the Asian population). Additionally, inhibition of P-glycoprotein intestinal efflux transporter by clarithromycin may also contribute to the interaction, resulting in increased bioavailability of lansoprazole.', 'DDInter', 'Although lansoprazole is generally well tolerated, caution may be advised during coadministration with clarithromycin, particularly if higher dosages of one or both drugs are used. Dosage adjustment may be necessary in patients who experience excessive adverse effects of lansoprazole.', 'Metabolism', 'Although lansoprazole is generally well tolerated, caution may be advised during coadministration with clarithromycin, particularly if higher dosages of one or both drugs are used.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67737/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67651, 'Diazepam', 'Clarithromycin', 'Moderate', 'Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.', 'DDInter', 'Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.', 'Metabolism', 'Patients receiving this combination should be monitored for excessive or prolonged sedation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67738/', '', 'Meprobamate', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67652, 'Dicloxacillin', 'Clarithromycin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67739/', '', 'Tazobactam, Sulbactam', 'Tinidazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67653, 'Dicoumarol', 'Clarithromycin', 'Major', 'Coadministration with clarithromycin or erythromycin may infrequently but substantially enhance the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism of interaction is unknown. Data from clinical studies have not supported a significant, predictable pharmacodynamic or pharmacokinetic interaction in general. Although both macrolides are potent inhibitors of CYP450 3A4 and can inhibit metabolism of the R(+) enantiomer of warfarin, the overall effect on racemic warfarin pharmacokinetics appears to be minor.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones) and other similar macrolides (e.g., troleandomycin), although clinical data are lacking.', 'Metabolism', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67740/', '', 'Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 'Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Vonoprazan, Dirithromycin, Lincomycin, Troleandomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67654, 'Dienestrol (topical)', 'Clarithromycin', 'Moderate', 'RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.', 'DDInter', 'Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67741/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67655, 'Diethylstilbestrol', 'Clarithromycin', 'Moderate', 'RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.', 'DDInter', 'Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67742/', '', 'Bazedoxifene', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67656, 'Digitoxin', 'Clarithromycin', 'Moderate', 'Macrolide antibiotics that inhibit P-glycoprotein may increase the plasma concentrations of digoxin. The proposed mechanism is inhibition of the P-glycoprotein-mediated intestinal efflux and/or renal tubular secretion of digoxin. The interaction has been described in numerous case reports in the medical literature, the majority of which involved clarithromycin, a potent P-glycoprotein inhibitor. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Exposure to macrolides, specifically clarithromycin, azithromycin and erythromycin, has been identified as a risk factor for digoxin toxicity.', 'DDInter', 'Caution is advised when digoxin or digitoxin is used in combination with macrolide antibiotics that are inhibitors of P-glycoprotein. Serum digitalis levels and pharmacologic effects should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of the macrolide in patients who are stabilized on their digitalis regimen. Patients should be advised to notify their physician if they experience signs of digitalis toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeats.', 'Absorption, Excretion', 'Caution is advised when digoxin or digitoxin is used in combination with macrolide antibiotics that are inhibitors of P-glycoprotein.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67743/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Esomeprazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67657, 'Digoxin', 'Clarithromycin', 'Major', 'Coadministration with clarithromycin may significantly increase the plasma concentrations of digoxin. The proposed mechanism is clarithromycin inhibition of the P-glycoprotein-mediated intestinal efflux and/or renal tubular secretion of digoxin.', 'DDInter', 'Caution is advised if digoxin must be used in combination with clarithromycin. Serum digoxin levels and pharmacologic effects should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of clarithromycin in patients who are stabilized on their digitalis regimen. Patients should be advised to notify their physician if they experience signs of digoxin toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeats.', 'Excretion', 'Caution is advised if digoxin must be used in combination with clarithromycin.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67744/', '', 'Tinidazole, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Dirithromycin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67658, 'Dihydroergotamine', 'Clarithromycin', 'Major', 'Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.', 'DDInter', 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.', 'Metabolism', 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67745/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67659, 'Disopyramide', 'Clarithromycin', 'Major', 'Disopyramide can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). Some macrolides such as clarithromycin, erythromycin, and troleandomycin are also potent inhibitors of CYP450 3A4 and may significantly inhibit the metabolism of disopyramide, which is thought to be a substrate of the isoenzyme.', 'DDInter', 'The concurrent use of disopyramide with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism, Synergism', 'The concurrent use of disopyramide with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67746/', '', 'Tocainide, Moricizine, Bretylium', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67660, 'Clarithromycin', 'Valproic acid', 'Moderate', 'A single case has been reported in which a patient developed seizures associated with elevated blood valproate levels after erythromycin was added to a stable valproate regimen. The seizures and elevated valproate levels resolved after both drugs were withheld. The patient subsequently tolerated her usual valproate dosage. The mechanism is suspected to be inhibition of the hepatic metabolism of valproate.', 'DDInter', 'While more data are needed, clinicians are encouraged to be aware that this interaction is possible when macrolide antimicrobial agents and valproate are coadministered. Patients should be advised to notify their physicians if they experience weakness, fatigue, confusion, ataxia, increased seizures, nausea, or vomiting.', 'Metabolism', 'While more data are needed, clinicians are encouraged to be aware that this interaction is possible when macrolide antimicrobial agents and valproate are coadministered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67747/', '', 'Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More', 'Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67661, 'Docetaxel', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.', 'DDInter', 'Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided. Some authorities recommend avoiding concomitant use of docetaxel during and for 2 weeks after treatment with itraconazole. If concomitant use is required, a reduced dosage of docetaxel should be considered. Based on extrapolation from the pharmacokinetic study in 7 cancer patients, a 50% reduction in the docetaxel dose may be reasonable. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paraesthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea.', 'Metabolism', 'Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67748/', '', 'Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin', 'Topotecan, Teniposide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67662, 'Dofetilide', 'Clarithromycin', 'Major', 'Like other class III antiarrhythmic agents, dofetilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67749/', '', 'Tocainide, Moricizine, Bretylium', 'Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Amoxicillin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67663, 'Dolasetron', 'Clarithromycin', 'Major', 'Dolasetron can cause dose-related prolongation of the QT interval via its pharmacologically active metabolite, hydrodolasetron. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG monitoring may be appropriate in high-risk patients. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67750/', '', 'Scopolamine, Nabilone, Rolapitant, Dronabinol', 'Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67664, 'Donepezil', 'Clarithromycin', 'Minor', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67751/', '', 'Memantine, Ginkgo biloba, Aducanumab', 'Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Dirithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67665, 'Doravirine', 'Clarithromycin', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67752/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67666, 'Doxazosin', 'Clarithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and effects of doxazosin. In vitro studies suggest that the primary pathway for elimination of doxazosin is via CYP450 3A4.', 'DDInter', 'Caution is advised if doxazosin is used concomitantly with potent CYP450 3A4 inhibitors. Blood pressure and pharmacologic response to doxazosin should be monitored closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the doxazosin dosage adjusted if necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.', 'Metabolism', 'Caution is advised if doxazosin is used concomitantly with potent CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67753/', '', 'Guanethidine', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67667, 'Doxepin', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67754/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine, Clemastine, Tetracaine, More', 'Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Dirithromycin, Lincomycin, Troleandomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67668, 'Doxorubicin', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67755/', '', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67669, 'Doxorubicin (liposomal)', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67756/', '', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67670, 'Dronedarone', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of dronedarone, which is primarily metabolized by the isoenzyme. Because dronedarone is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', 'DDInter', 'The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated. Patients currently receiving these agents should stop taking them before starting treatment with dronedarone. Some authorities consider concomitant administration of dronedarone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67757/', '', 'Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, More', 'Tocainide, Moricizine, Bretylium', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67671, 'Droperidol', 'Clarithromycin', 'Major', 'The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins), drugs known to increase the QT interval (e.g., phenothiazines, tricyclic antidepressants, antiarrhythmic agents, etc.), certain other drugs (benzodiazepines, volatile anesthetics, intravenous opiates), or alcohol abuse may increase the risk of prolonged QT syndrome.', 'DDInter', 'The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Synergism', 'The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67758/', '', 'Loxapine, Molindone, Thiothixene', 'Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67672, 'Drospirenone', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67759/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67673, 'Dulaglutide', 'Clarithromycin', 'Moderate', 'Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.', 'DDInter', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Metabolism', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67760/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67674, 'Dutasteride', 'Clarithromycin', 'Moderate', 'Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67761/', '', 'Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Amoxicillin, Dirithromycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67675, 'Duvelisib', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The dosage of duvelisib should be reduced to 15 mg twice daily when used with potent CYP450 3A4 inhibitors. Patients should be closely monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.', 'Metabolism', 'The dosage of duvelisib should be reduced to 15 mg twice daily when used with potent CYP450 3A4 inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67762/', '', 'Tetracycline, Levofloxacin, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Vonoprazan, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67676, 'Echinacea', 'Clarithromycin', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67763/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67677, 'Edoxaban', 'Clarithromycin', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of edoxaban, which is a substrate of the efflux transporter.', 'DDInter', 'When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil. This dosage recommendation is based on data from a clinical study, the Hokusai VTE study, and is limited to use with the specific P-gp inhibitors mentioned.', 'Absorption', 'When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67764/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67678, 'Efavirenz', 'Clarithromycin', 'Moderate', 'Efavirenz has been shown to decrease the area under the plasma concentration-time curve of clarithromycin (500 mg every 12 hours) by 39%. This interaction is attributable to the enhanced metabolism of clarithromycin caused by efavirenz.', 'DDInter', 'The manufacturer recommends that alternative therapy such as azithromycin be considered. No dosage adjustments are recommended. If concomitant therapy cannot be avoided, the patient should be monitored for decreased therapeutic effect of clarithromycin.', 'Metabolism', 'The manufacturer recommends that alternative therapy such as azithromycin be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67765/', '', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More', 'Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Amoxicillin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67679, 'Elagolix', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme. Increased exposure to elagolix may increase the risk of serious adverse effects such as bone loss, suicidal ideation and behavior, exacerbation of mood disorders, and hepatic transaminase elevations.', 'DDInter', 'Concomitant use of elagolix 200 mg twice daily with potent CYP450 3A4 inhibitors for more than 1 month, or elagolix 150 mg once daily with potent CYP450 3A4 inhibitors for more than 6 months, is not recommended.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67766/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67680, 'Eletriptan', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eletriptan, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in increased risk of vasospastic reactions associated with the use of 5-HT1 receptor agonists, such as coronary artery vasospasm, peripheral vascular ischemia, and colonic ischemia.', 'DDInter', 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors. Alternatively, other 5-HT1 receptor agonists that are not metabolized by CYP450 3A4 may be considered, such as frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.', 'Metabolism', 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67767/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab', 'Tinidazole, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Nizatidine, Esomeprazole, Amoxicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67681, 'Eliglustat', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.', 'DDInter', 'The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.', 'Metabolism', 'The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67768/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67682, 'Eluxadoline', 'Clarithromycin', 'Moderate', 'It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.', 'DDInter', 'As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,', 'Metabolism', 'As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67769/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Opium, Diphenoxylate, Difenoxin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67683, 'Empagliflozin', 'Clarithromycin', 'Moderate', 'Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.', 'DDInter', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Metabolism', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67770/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67684, 'Encorafenib', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.', 'DDInter', 'Concomitant use of encorafenib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-third of the dose used prior to addition of the potent CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', 'Concomitant use of encorafenib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67771/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67685, 'Enfortumab vedotin', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67772/', '', 'Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67686, 'Entrectinib', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.', 'DDInter', 'Concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the dosage of entrectinib should be reduced to 100 mg once daily for adults and pediatrics patients (12 years and older) with a body surface area (BSA) greater than 1.5 m2. Following discontinuation, and after an appropriate washout period of the CYP450 3A4 inhibitor (i.e., 3 to 5 half-lives), the entrectinib dosage taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided.', 'Metabolism', 'Concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided when possible.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67773/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67687, 'Enzalutamide', 'Clarithromycin', 'Moderate', 'Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.', 'DDInter', 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67774/', '', 'Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Nizatidine, Ranitidine, Amoxicillin, Lincomycin, Dirithromycin', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67688, 'Epirubicin', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', 'DDInter', 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67775/', '', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67689, 'Eplerenone', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67776/', '', 'Amiloride, Triamterene', 'Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67690, 'Eravacycline', 'Clarithromycin', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of eravacycline, which undergoes oxidation by CYP450 3A4 and flavin monoxygenase (FMO).', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67777/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Omadacycline, Sarecycline, Oxytetracycline, Demeclocycline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67691, 'Erdafitinib', 'Clarithromycin', 'Major', 'Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 may increase the plasma concentrations and risk of toxicity of erdafitinib, which is a substrate of these isoenzymes.', 'DDInter', 'Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided. If concomitant use is unavoidable, patients should be closely monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring of erdafitinib should be considered whenever a CYP450 2C9 or 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67778/', '', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67692, 'Ergometrine', 'Clarithromycin', 'Major', 'Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.', 'DDInter', 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.', 'Metabolism', 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67779/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More', 'Dinoprostone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67693, 'Ergotamine', 'Clarithromycin', 'Major', 'Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.', 'DDInter', 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.', 'Metabolism', 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67780/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67694, 'Eribulin', 'Clarithromycin', 'Moderate', 'Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67781/', '', 'Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67695, 'Erlotinib', 'Clarithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.', 'Metabolism', 'Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67782/', '', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67696, 'Ertugliflozin', 'Clarithromycin', 'Moderate', 'Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.', 'DDInter', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.', 'Metabolism', 'Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67783/', '', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67697, 'Erythromycin', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme. The use of erythromycin has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes. In addition, erythromycin may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.', 'DDInter', 'Concomitant use of erythromycin with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67784/', '', 'Clarithromycin, Lincomycin, Troleandomycin, Dirithromycin, Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Rifamycin, Oxytetracycline, More', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Erythromycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67698, 'Escitalopram', 'Clarithromycin', 'Major', 'Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67785/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine', 'Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Ranitidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67699, 'Esomeprazole', 'Clarithromycin', 'Minor', 'Clarithromycin may increase the plasma concentration of esomeprazole. The mechanism may be related to clarithromycin inhibition of hepatic cytochrome P450 enzymes responsible for esomeprazole metabolism. The systemic exposure (AUC) to esomeprazole doubled after coadministration with clarithromycin 500 mg twice daily. The clinical significance is unknown and dose adjustments are not required.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67786/', '', 'Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin, Fenoprofen, Meclofenamic acid, Phenylbutazone, Glucosamine, Chondroitin sulfate, Piroxicam, Flurbiprofen, More', 'Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (67700, 'Estazolam', 'Clarithromycin', 'Moderate', 'Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.', 'DDInter', 'Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.', 'Metabolism', 'Patients receiving this combination should be monitored for excessive or prolonged sedation.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67787/', '', 'Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, More', 'Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More', 1767369485);
